Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
Fresenius Kabi is hiring 2 roles related to this product
BLEOMYCIN SULFATE (bleomycin sulfate) by Fresenius Kabi is clinical pharmacology: mechanism of action although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of dna synthesis with some evidence of lesser inhibition of rna and protein synthesis. Approved for lymphoma, lymphoma. First approved in 2008.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY: Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. Bleomycin is known to cause…
Worked on BLEOMYCIN SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moFresenius Kabi is hiring 2 roles related to this product